Credit: Shutterstock photoThe Relative Strength ( RS ) Rating for Neogen ( NEOG ) entered a higher percentile Friday, as it got a lift from 68 to 74.
[ibd-display-video id=2368044 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves. See if Neogen can continue to show renewed price strength and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Neogen is working on a consolidation with a 64.52 entry . See if it can clear the breakout price in heavy volume.
Earnings growth rose last quarter from 15% to 18%. But revenue gains fell from 14% to 12%.
The company earns the No. 13 rank among its peers in the Medical-Products industry group. Abiomed ( ABMD ), Align Technology ( ALGN ) and Edwards Lifesciences ( EW ) are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
